Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.ents. Correlates with Alzheimer disease
Keywords: 
Basal ganglia
Receptor heteromer
Heteromer-selective antagonist
Neuroprotection
Postsynaptic heteromer
Presynaptic heteromer
Issue Date: 
Dec-2011
Publisher: 
Pergamon Elsevier Science LTD
ISSN: 
0163-7258
Citation: 
Armentero MT, Pinna A, Ferre S, Lanciego JL, Muller CE, Franco R. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther 2011 Dec;132(3):280-299.
Abstract
Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market. The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia. At present it is believed that A2AR antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson's patients. However, a considerable body of data indicates that in addition to ameliorating motor symptoms, adenosine A2AR antagonists may also prevent neurodegeneration. Despite these promising indications, one further issue must be considered in order to develop fully optimized antiparkinsonian drug therapy, namely the existence of (hetero)dimers/oligomers of G protein-coupled receptors, a topic that is currently the focus of intense debate within the scientific community. Dopamine D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine receptors. Thus, the development of heteromer-specific A2A receptor antagonists represents a promising strategy for the identification of more selective and safer drugs.

Files in This Item:
There are no files associated with this item.


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.